Maravai LifeSciences impresses with Q4 2023 revenue of $74.1 million, surpassing estimates. CEO Trey Martin highlights strong execution, cost reductions, and a 28% adjusted EBITDA margin. 2024 revenue guidance of $265-$285 million exceeds expectations.
By Josh Beckerman Shares of Maravai LifeSciences Holdings surged 65% to $8.41 after it reported a 64% fourth-quarter revenue decline amid lower demand from.
Health care stocks rose Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund both up 0.3%.
The iShares Biotechnology ETF climbed 0.8%.
In corporate news,.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call Transcript February 23, 2024 Maravai LifeSciences Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and thank you for standing by. At this time, we would like to […]